Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia.
Centre for Health Economics, Monash Business School, Monash University, Melbourne, VIC, Australia.
Pharmacoeconomics. 2024 Jun;42(Suppl 1):147-161. doi: 10.1007/s40273-024-01355-1. Epub 2024 Jan 27.
This study examines the psychometric properties of the Child Health Utility 9D (CHU9D) proxy version administered to parents/caregivers of 2-4-year-old Australian children compared with Pediatric Quality of Life Inventory™ version 4.0 (PedsQL).
Data collected in 2021/2022 from parents/caregivers of 2-4-year-olds from the Australian pediatric multi-instrument comparison study were used. Feasibility, ceiling/floor effects, test-retest reliability, convergent validity, known-group validity, and responsiveness were assessed.
A total of 842 caregivers completed the survey at baseline, with 513 completing the follow-up survey. The CHU9D did not demonstrate ceiling effects in the sample with special health care needs, with only 6% of respondents reporting best levels for all nine dimensions. CHU9D correlated with PedsQL moderately-to-strongly between comparable items (correlation coefficients 0.34-0.70). CHU9D was able to differentiate between groups with known health differences with moderate-to-large effect sizes (Cohen's d 0.58-2.03). Moderate test-retest reliability was found for CHU9D in those reporting no health change at a 2-day follow-up (ICC 0.52). A standard response mean (SRM) of 0.25-0.44 was found for children with changes in general health and a SRM of 0.72-0.82 for children who reported worsened health when developing new illnesses, indicating small-to-large responsiveness according to different definitions of health changes. Compared with PedsQL, CHU9D had similar known-group validity and responsiveness and slightly poorer test-retest reliability.
The CHU9D was found to be valid and reliable to measure health-related quality-of-life in children aged 2-4 years, although with relatively low test-retest reliability in some dimensions. Further development and validation work is warranted.
本研究考察了儿童健康效用 9 维度（CHU9D）代理版本在澳大利亚 2-4 岁儿童的父母/照顾者中的心理测量特性，与儿科生活质量量表 4.0（PedsQL）版本进行比较。
使用 2021/2022 年澳大利亚儿科多仪器比较研究中父母/照顾者收集的数据。评估了可行性、天花板/地板效应、测试-重测信度、收敛效度、已知组有效性和反应度。
共有 842 位照顾者在基线时完成了调查，其中 513 位完成了随访调查。CHU9D 在有特殊医疗需求的样本中没有表现出天花板效应，只有 6%的受访者报告了所有九个维度的最佳水平。CHU9D 与 PedsQL 在可比项目之间呈中等到强相关（相关系数 0.34-0.70）。CHU9D 能够区分具有已知健康差异的组，具有中到大的效应大小（Cohen's d 0.58-2.03）。在报告无健康变化的 2 天随访时，CHU9D 的测试-重测信度中等（ICC 0.52）。对于一般健康状况发生变化的儿童，发现标准反应均值（SRM）为 0.25-0.44，对于报告新疾病时健康状况恶化的儿童，SRM 为 0.72-0.82，根据健康变化的不同定义，表明反应性为小到大。与 PedsQL 相比，CHU9D 具有相似的已知组有效性和反应性，测试-重测信度略差。
CHU9D 被发现可用于测量 2-4 岁儿童的健康相关生活质量，尽管在某些维度上的测试-重测信度相对较低。需要进一步开发和验证工作。
Zotero 插件